Up­dat­ed: Any­one still look­ing for a CD47? Zai Lab shelves PhI pro­gram af­ter re­view­ing 'com­pet­i­tive land­scape'

Over the past few years, the promise of block­ing CD47 — a “don’t eat me” sig­nal co-opt­ed by can­cer cells — has sent drug­mak­ers big and small in­to a fren­zy. But one biotech is now bow­ing out.

Zai Lab is de­pri­or­i­tiz­ing ZL-1201, its CD47 in­hibitor, scrap­ping plans for a Phase II tri­al. It will now “pur­sue out-li­cens­ing op­por­tu­ni­ties,” the com­pa­ny said in its Q2 up­date. The de­ci­sion was based on a re­view of the com­pet­i­tive land­scape, it added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER